IRIS Institutional Research Information System - OPENBS Open Archive UniBS

QUIROS ROLDAN, MARIA EUGENIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.695
AS - Asia 11.950
EU - Europa 8.784
SA - Sud America 2.311
Continente sconosciuto - Info sul continente non disponibili 663
AF - Africa 260
OC - Oceania 40
Totale 48.703
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.156
SG - Singapore 4.102
CN - Cina 3.690
BR - Brasile 1.868
UA - Ucraina 1.777
HK - Hong Kong 1.488
IT - Italia 1.461
DE - Germania 1.436
VN - Vietnam 750
FI - Finlandia 723
PL - Polonia 679
GB - Regno Unito 629
FR - Francia 575
RU - Federazione Russa 465
BD - Bangladesh 451
TR - Turchia 405
IN - India 391
IE - Irlanda 378
CA - Canada 277
AR - Argentina 144
MX - Messico 128
NL - Olanda 122
SE - Svezia 113
ES - Italia 96
ID - Indonesia 95
IQ - Iraq 90
EC - Ecuador 87
JP - Giappone 86
ZA - Sudafrica 83
AT - Austria 76
PK - Pakistan 58
CO - Colombia 50
SA - Arabia Saudita 45
CZ - Repubblica Ceca 43
VE - Venezuela 43
UZ - Uzbekistan 39
AU - Australia 38
JM - Giamaica 33
LT - Lituania 33
BE - Belgio 32
IR - Iran 31
CL - Cile 30
MA - Marocco 29
PY - Paraguay 29
EG - Egitto 26
CR - Costa Rica 25
KE - Kenya 24
IL - Israele 22
AE - Emirati Arabi Uniti 21
JO - Giordania 21
NG - Nigeria 21
UY - Uruguay 21
MY - Malesia 20
PE - Perù 20
CH - Svizzera 19
DZ - Algeria 17
PH - Filippine 17
BO - Bolivia 16
TN - Tunisia 16
AZ - Azerbaigian 14
EU - Europa 14
RO - Romania 14
HN - Honduras 13
HU - Ungheria 13
KZ - Kazakistan 12
PA - Panama 11
EE - Estonia 10
ET - Etiopia 10
MU - Mauritius 10
RS - Serbia 10
TH - Thailandia 10
AM - Armenia 9
BB - Barbados 9
NP - Nepal 9
OM - Oman 9
TT - Trinidad e Tobago 9
AL - Albania 8
KR - Corea 8
LV - Lettonia 8
PT - Portogallo 8
BG - Bulgaria 7
BY - Bielorussia 7
DO - Repubblica Dominicana 7
HR - Croazia 7
GE - Georgia 6
GT - Guatemala 6
LB - Libano 6
NI - Nicaragua 6
SK - Slovacchia (Repubblica Slovacca) 6
BH - Bahrain 5
KG - Kirghizistan 5
MK - Macedonia 5
MN - Mongolia 5
PR - Porto Rico 5
SI - Slovenia 5
UG - Uganda 5
CI - Costa d'Avorio 4
LK - Sri Lanka 4
MD - Moldavia 4
SC - Seychelles 4
Totale 47.987
Salva come PNG Salva come JPEG
Città #
Ashburn 2.314
Fairfield 2.269
Singapore 2.224
Woodbridge 1.906
Hong Kong 1.485
Jacksonville 1.343
Houston 1.277
San Jose 1.212
Seattle 957
Cambridge 916
Wilmington 883
Ann Arbor 839
Chandler 731
The Dalles 710
Warsaw 666
Beijing 657
Princeton 634
New York 594
Council Bluffs 584
Los Angeles 494
Nanjing 469
Helsinki 441
Dublin 369
Lauterbourg 360
Columbus 328
Istanbul 319
Dallas 278
Ho Chi Minh City 249
Munich 228
Buffalo 204
Des Moines 196
São Paulo 193
Nanchang 190
Brescia 185
Dearborn 183
Moscow 181
Milan 178
Chicago 158
Santa Clara 152
Hanoi 145
San Francisco 145
Shanghai 142
San Diego 139
Changsha 133
Shenyang 131
Hebei 124
Redondo Beach 121
Jinan 113
London 104
Lancaster 100
Frankfurt am Main 96
Phoenix 91
Tianjin 91
Orem 87
Tokyo 79
Montreal 78
Nuremberg 78
Toronto 76
Hangzhou 69
Brooklyn 68
Turku 66
Atlanta 65
Jiaxing 65
Kunming 59
Denver 57
Rio de Janeiro 55
Chennai 54
Rome 52
Guangzhou 50
Johannesburg 45
Mexico City 45
Charlotte 44
Verona 44
Zhengzhou 44
Manchester 43
Belo Horizonte 42
Jakarta 41
Washington 41
Boston 40
Brasília 40
Ningbo 38
Porto Alegre 38
Amsterdam 37
Boardman 37
Haiphong 36
Stockholm 36
Tashkent 36
Poplar 35
Brno 32
Curitiba 32
Da Nang 32
Düsseldorf 32
Baghdad 30
Brussels 30
Dong Ket 30
Kocaeli 29
Romola 29
Taizhou 29
Vienna 29
Guayaquil 27
Totale 31.412
Salva come PNG Salva come JPEG
Nome #
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses 598
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 504
The impact of antiretroviral therapy on iron homeostasis and inflammation markers in HIV-infected patients with mild anemia 300
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study 282
Modulation of Regulatory T-cell Subsets in Very Long-term Treated Aviremic HIV(+) Patients and Untreated Viremic patients 264
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA 260
Effectiveness of routine lumbar puncture in patients with HIV-associated Dementia (HAD) receiving suppressive antiretroviral treatment 254
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz 244
Burden of Non-AIDS-Defining and Non-Virus-Related Cancers Among HIV-Infected Patients in the Combined Antiretroviral Therapy Era. 230
Cohort profile: Standardized management of antiretroviral therapy cohort (MASTER cohort) 230
The evolving burden of HIV infection compared with other chronic diseases in northern Italy 214
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 208
Prevalence of integrase strand transfer inhibitors (InSTIs) resistance mutations in InSTIs-naive and -experienced HIV-1 infected patients: a single Center experience 207
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 206
Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy 205
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 203
Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection 202
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study 198
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study 194
Hepatitis C infection influence on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3 193
Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients 190
Cryptogenic liver diseases: sailing by sight from HIV co-infection with hepatitis viruses to HIV mono-infection through the Pillars of Hercules. 190
A first update on mapping the human genetic architecture of COVID-19 188
HIV-associated asymmetric lipodystrophy syndrome 187
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy 187
Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. 185
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART. 184
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 184
Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy 183
Compassionate Use of Remdesivir for Patients with Severe Covid-19 183
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. 183
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 182
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. 181
Mapping the human genetic architecture of COVID-19 180
An enzyme-linked (alkaline phosphatase) oligonucleotide probe for the detection of serum hepatitis B virus DNA. 178
Decrease of HCVRNA after three days of daily interferon treatment is predictive of the virological response at one month 177
Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012 177
A population-based database to study malignancies in HIV-infected patients in the Local Health Unit of Brescia (Northern Italy), period 1999-2009 175
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 174
Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome 173
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: Routine evidence from the Italian MASTER Cohort 173
Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting 172
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy 172
Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone 171
Bcl-2 expression is moderately correlated with long-term variability of CD4+ T-cell increase under successful highly active antiretroviral therapy 171
Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications. 171
Breast cancer among human immunodeficiency virus (HIV)-infected patients: the experience in Brescia, Northern Italy. 170
Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort 170
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naive for lopinavir with limited exposure to previous protease inhibitors. 170
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study 170
Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults 169
Consequences of the COVID-19 pandemic on the continuum of care in a cohort of people living with HIV followed in a single center of Northern Italy 169
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. 168
Lung cancer in HIV-infected patients: the experience in Brescia from 1999 to 2009 168
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 168
Successful long-course after failure of short-course desensitization in a patient with severe hypersensitivity reaction to enfuvirtide 166
Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature 166
Effects of combined antiretroviral therapy on B- and T-cell release from production sites in long-term treated HIV-1+ patients 166
An explainable model of host genetic interactions linked to COVID-19 severity 165
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients 165
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 164
A COPD case-finding program in a large cohort of HIV-infected persons 164
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? 163
HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir containing regimens 160
Prevalence of non-B HIV-1 subtypes in North Italy and analysis of transmission clusters based on sequence data analysis 160
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. 158
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations 158
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI 158
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 158
The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population 158
Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment 157
The predictive role of NLR and PLR for solid non-AIDS defining cancer incidence in HIV-infected subjects: a MASTER cohort study 157
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? 156
Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-Naïve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir 156
Peripheral loss of regulatory T cells and polyautoimmunity in an HIV-infected patient 156
Analisi estensiva di sequenza dei geni della trascrittasi inversa e della proteasi di HIV-1 in una coorte clinica di pazienti HIV positivi NAIVE per la terapia antiretrovirale. 155
Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of northern Italy,1999-2009 155
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 154
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. 153
Elderly women with human immunodeficiency virus infection: is there an effect of the virus on neuropsychological prolife? 153
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. 153
Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy 152
Impact of detectable human cytomegalovirus DNAemia on viro-immunologicaleffectiveness of HAART in HIV-infected patients naive to antiretroviral therapy 152
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 152
CD4+ T cell evolution and predictors of its trend before and aftertenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 151
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. 149
Detection of clonal T cell populations with closely related T cell receptor junctional sequences in persons at high risk for human immunodeficiency virus (HIV) infection and in patients acutely infected with HIV 149
Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort 149
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients 149
Lymphocyte homeostasis is maintained in perinatally HIV-infected patients after three decades of life 148
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 147
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir 147
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 147
HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations 147
An outbreak of Serratia marcescens bloodstream infections associated with misuse of drug vials in a surgical ward 146
Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells 146
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 146
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy 145
Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy 144
Totale 18.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 246.624
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 246.624
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.952 0 0 75 149 37 133 155 183 127 298 208 587
2022/20232.341 354 69 46 152 185 635 10 227 381 38 112 132
2023/20242.499 130 72 224 196 107 423 78 108 647 30 70 414
2024/20256.810 81 45 74 788 748 643 687 229 782 662 1.254 817
2025/202614.833 1.309 1.736 1.022 1.996 1.660 995 2.056 599 975 1.253 698 534
2026/20272.592 900 933 759 0 0 0 0 0 0 0 0 0
Totale 48.703